Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Items | Size （2mg） | Size（5mg X 2） |
| Particle size | 2 μm | 2 μm |
| Physical appearance | Powder mixture | Powder mixture |
| Amount of Coupled Protein | ≈1254 pmol (36 μg) Spike RBD/mg Beads | ≈1254 pmol (36 μg) Spike RBD/mg Beads |
| Binding Capacity | >40 μg anti-SARS2-CoV-2 Spike S1 antibody/mg beads; >40 μg ACE2 protein / mg beads | >40 μg anti-SARS2-CoV-2 S1 antibody/mg beads; >40 μg ACE2 protein / mg beads |
| Formulation | PBS, pH7.4, with 10% Trehalose | PBS, pH7.4, with 10% Trehalose |
| Reconstitution | 2 mL sterile deionized water (1 mg beads/mL) | 5 mL sterile deionized water (1 mg beads/mL) |
See Certificate of Analysis (CoA) for detailed instruction.
The magnetic beads technology makes use of the easy and efficient collection of beads in magnetic field to facilitate antibody purification in a simple workflow of “bind-wash-elute”. In contrast to common separation techniques, this method does not require columns or centrifugation, and is therefore ideal in high-throughput applications.
Please contact us for detailed information.
Contact us for customized product form or formulation.
Immobilized 40 μg SARS-CoV-2 S protein RBD to 1mg Beads, can bind the Anti-SARS-CoV-2 Spike S1 Antibody with an EC50 of 0.8887 μg/mL.
Immobilized 40 μg SARS-CoV-2 S protein RBD to 1mg Beads, can bind the Human ACE2, Fc Tag (AC2-H5257) with an EC50 of 1.008 μg/mL.
The binding curves between SARS-CoV-2 S RBD pre-coupling magnetic beads (Cat. No. MBS-K002) after different freeze-thaw cycles and anti-SARS-CoV-2 S1 antibody. 0.1 mg of Beads (1 mg/ml, 100 μl) was washed three times and the supernatant was removed. 100 μL antibodies of the corresponding concentration (10 μg/ml-0.039 μg/ml) were added. Fluorescent labeled secondary antibody was added for detection (Routinely tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.
A-Z
